Marijuana can raise liver enzymes, and the effect is most clearly documented with cannabidiol (CBD) at therapeutic doses. A 2024 randomized trial found that roughly 6% of healthy adults taking CBD developed significant elevations in ALT, a key marker of liver-cell injury, after just four weeks. But the relationship between cannabis and the liver is not a simple story of harm. THC, the compound responsible for the high, is processed almost entirely by the liver and interacts with a network of receptors that can push liver health in opposite directions depending on the circumstances. Whether marijuana helps or hurts the liver depends on which cannabinoid you’re talking about, how much you’re using, what other medications are in the mix, and whether you already have liver disease.
How Cannabis Travels Through the Liver
When you smoke or vape marijuana, THC reaches peak blood levels within about six to ten minutes and quickly travels to the liver, where most of it is broken down into metabolites called 11-OH-THC and 11-COOH-THC. The bioavailability of inhaled THC ranges from about 10% to 35%. If you eat an edible instead, the liver gets first crack at the entire dose before any THC reaches your brain, which is why bioavailability drops to roughly 4% to 12%.1PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis This “first-pass” processing means the liver handles a heavy workload every time you consume cannabis, and it means the route of administration changes how much cannabinoid your liver sees relative to the rest of your body.
Both THC and CBD are broken down by the same family of liver enzymes, the cytochrome P450 system, that metabolizes a huge share of prescription drugs. CBD and THC can inhibit several of these enzymes, including CYP2C9, CYP2C19, and CYP3A4.2PubMed Central. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes That inhibition is the reason cannabis can alter the blood levels of other drugs you’re taking, and it also sets the stage for the liver-enzyme elevations that show up in clinical trials.
CBD Is the Bigger Culprit for Liver Enzyme Elevations
The most convincing evidence of cannabis-related liver stress comes not from THC but from CBD, particularly at the high doses used to treat epilepsy and other conditions. In a randomized, placebo-controlled trial published in JAMA Internal Medicine, about 5.6% of healthy adults receiving CBD developed ALT levels more than three times the upper limit of normal within four weeks. Nobody in the placebo group hit that threshold.3JAMA Internal Medicine. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial These aren’t trivially elevated numbers. An ALT level triple the upper limit is the standard alarm bell for drug-induced liver injury.
An earlier open-label trial painted an even starker picture. Sixteen healthy volunteers took a therapeutic CBD dose of about 1,500 mg per day for roughly three and a half weeks. Nearly half of them developed peak ALT values above normal, and almost a third met the international criteria for drug-induced liver injury, with ALT values five times the upper limit.4PubMed Central. Metabolism and liver toxicity of cannabidiol That trial also showed increases in AST and GGT, two other enzymes that signal liver trouble.
A meta-analysis pulling together data from multiple trials confirmed the pattern across larger populations. Compared with placebo, CBD was associated with roughly a sixfold higher risk of liver-enzyme elevation and nearly a fivefold higher risk of drug-induced liver injury.5PubMed Central. Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review High dose and concurrent use of certain anti-seizure medications were identified as risk factors. No cases of outright liver failure were reported, but that comes with a caveat: in most trials, CBD was reduced or stopped when enzymes climbed. Nobody knows what would have happened if those participants had kept taking the same dose.
These findings matter because CBD products are widely available without a prescription, often at doses much lower than those used in clinical trials. Whether the CBD gummies or tinctures sold at dispensaries and gas stations carry the same risk is genuinely unclear. Trial doses for epilepsy run around 10 to 20 mg per kilogram of body weight per day, which for an average adult translates to roughly 700 to 1,500 mg daily. Most over-the-counter products deliver 25 to 50 mg per dose. The risk almost certainly scales with how much you take, but nobody has run a large trial at low, consumer-level doses specifically to check liver enzymes.
What About THC and Everyday Marijuana Use?
THC’s direct effect on liver enzymes in otherwise healthy people is harder to pin down because the research is thinner and more observational. One small study of chronic marijuana smokers found mildly elevated AST in about 42% and ALT in about 35%, along with elevated alkaline phosphatase in over half the group.6PubMed Central. Possible hepatotoxicity of chronic marijuana usage Those elevations were modest, though, and the study was small enough that confounding factors like diet and alcohol couldn’t be fully excluded. The group using both marijuana and alcohol showed the highest enzyme levels, which is a pattern that runs through much of the literature: cannabis seems to amplify liver stress when combined with another hepatotoxin.
Animal toxicology studies offer some additional perspective. When rats and rabbits were given cannabis extract daily for 120 days, only the highest-dose groups showed significant enzyme elevations, and even then, tissue samples of the liver looked morphologically normal under the microscope.7Toxicology Reports. Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs That suggests a dose threshold below which the liver handles cannabis without visible injury, at least in animals. Mouse studies with CBD alone tell a similar story: high doses caused cellular swelling in the liver, but lower doses did not.8PubMed Central. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model
Two Receptors, Two Opposite Effects
The liver has its own endocannabinoid signaling system, and it features two main receptor types that do very different things. CB1 receptors, when activated, promote fat production in the liver. Animal research has shown that stimulating CB1 ramps up the genes responsible for making new fatty acids, contributing to fat buildup in liver cells.9PubMed Central. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity That’s bad news if you’re worried about fatty liver disease.
CB2 receptors play a different role. They appear to be protective during liver injury. In chronic and acute liver injury models, CB2 activation has been linked to reduced fibrosis, less inflammation, and better outcomes.10PubMed Central. CB2 receptors as new therapeutic targets for liver diseases In one experiment, rats with bile duct injuries treated with a CB2-activating drug showed reduced scarring, lower levels of oxidative damage, and more anti-inflammatory signaling.11PubMed Central. CB2 Receptor Agonist Attenuates Inflammation, Apoptosis and Stimulate Progenitor Cells in Bile Duct Ligated Rats
THC activates both CB1 and CB2. So when you use marijuana, you’re simultaneously pushing the liver toward fat accumulation and pulling it toward anti-inflammatory protection. Which effect wins out likely depends on your existing liver health, the dose, and how long you’ve been using. This tug-of-war is a big part of why the epidemiological data on cannabis and liver disease can seem contradictory.
The Fatty Liver Paradox
One of the more surprising findings in the literature is that cannabis users appear less likely to have fatty liver disease than non-users. A recent systematic review and meta-analysis of nine studies found that cannabis users had about 42% lower odds of hepatic steatosis compared to non-users.12PubMed Central. A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer? This is counterintuitive given what we know about CB1 promoting liver fat, and researchers don’t have a fully satisfying explanation.
Some hypotheses include the possibility that cannabis users tend to have lower body mass indexes on average, that THC’s effects on insulin sensitivity play a role, or that CB2 activation counterbalances CB1-driven fat production in ways that aren’t yet fully mapped. Whatever the mechanism, the association has held up across multiple large population-based studies, so it isn’t a fluke of a single dataset.
But the picture has complications. A separate analysis of patients who already had non-alcoholic fatty liver disease found that those with a history of cannabis use had a higher prevalence of ascites, a condition where fluid accumulates in the abdomen, compared to non-users.13PubMed Central. Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis So while cannabis might be associated with a lower risk of developing fatty liver in the first place, it doesn’t necessarily help once the disease is already established. The rates of portal hypertension and cirrhosis were similar between users and non-users in that study.
Cannabis and Hepatitis C
For years, the clearest warning about cannabis and liver disease centered on hepatitis C. A study of patients with chronic hepatitis C found that daily cannabis use was associated with substantially higher odds of moderate to severe liver fibrosis compared to less frequent or no use.14PubMed Central. Influence of Cannabis Use on Severity of Hepatitis C Disease The association was strong enough that some hepatologists routinely advised hepatitis C patients to stop using marijuana.
However, when researchers later pooled results across multiple studies in a meta-analysis, the association between cannabis use and advanced fibrosis in hepatitis C patients was no longer statistically significant, though the trend still pointed toward higher risk.15PubMed. Use of cannabis and risk of advanced liver fibrosis in patients with chronic hepatitis C virus infection: A systematic review and meta-analysis The era of effective antiviral treatments for hepatitis C has also changed the landscape. With cure rates now above 95%, the question of whether cannabis accelerates hepatitis C fibrosis is less clinically urgent than it once was, though it remains relevant for untreated patients worldwide.
Cirrhosis Sends Mixed Signals
The data on cannabis and cirrhosis is genuinely contradictory, and it’s worth being upfront about that. One large study looked at hospitalized patients with cirrhosis after cannabis legalization in certain states and found that cannabis users had lower rates of admission for hepatorenal syndrome and ascites, shorter hospital stays, lower total charges, and lower in-hospital mortality compared to non-users.16PubMed. Cannabis use may reduce healthcare utilization and improve hospital outcomes in patients with cirrhosis Those are striking numbers that prompted real excitement about potential benefits.
But a separate propensity-matched analysis focusing on patients with cannabis use disorder told a different story. In that population, cannabis use was associated with higher all-cause mortality, more frequent critical care admissions, and higher rates of pneumonia and electrolyte disturbances.17PubMed Central. Unmasking the Burden of Cannabis in Cirrhosis: A Propensity-Matched Real-World Analysis The distinction between casual cannabis use and cannabis use disorder is probably important here. Heavy, problematic use may compound the systemic fragility of a cirrhotic liver in ways that moderate use does not.
There’s also a biological mechanism that could explain why cirrhosis and cannabis interact badly at high levels. In patients with cirrhosis, endocannabinoids produced by immune cells and platelets activate CB1 receptors in blood vessels and the heart, contributing to the low blood pressure and cardiac dysfunction that characterize advanced liver disease.18PubMed Central. Endocannabinoids in liver disease Adding external cannabinoids like THC on top of an already overactive endocannabinoid system could theoretically worsen these cardiovascular complications, though this has not been directly tested in controlled human studies.
Drug Interactions That Amplify Liver Risk
If you’re taking prescription medications alongside cannabis, the liver-enzyme story gets more complicated. The interaction between CBD and valproate, a common anti-seizure medication, is the best-studied example. Clinical trial data have shown that CBD’s risk of severe liver toxicity increases substantially when patients are also taking valproate.19PubMed Central. Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model The mechanism behind this interaction is not well understood. Computer modeling of the three major pathways of direct liver toxicity failed to predict the increased injury, suggesting something more complex is going on than simple additive damage.20PubMed. Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology
Beyond valproate, the broad inhibition of cytochrome P450 enzymes by CBD and THC means that virtually any drug metabolized through these pathways could interact. Statins, blood thinners, immunosuppressants, certain antidepressants, and many other common medications share these metabolic routes. If cannabis slows the breakdown of another drug, that drug’s blood levels rise, and so does the risk of its own side effects, including liver toxicity. This is an underappreciated concern for the growing number of people who use cannabis daily while also taking prescription medications.
Synthetic Cannabinoids Are a Different Story
Synthetic cannabinoids, often sold as “Spice” or “K2,” are chemically distinct from the cannabinoids in marijuana and have a much more alarming track record with liver injury. Case reports have documented acute liver injury in young, otherwise healthy individuals whose only identifiable toxic exposure was synthetic cannabinoid use. In one published case, a 22-year-old man presented with abdominal pain, vomiting, and jaundice after regular synthetic cannabinoid use, and after other causes of liver injury were ruled out, the synthetic cannabinoids were identified as the probable cause.21PubMed Central. Acute Liver Injury Induced by Synthetic Cannabinoid Abuse
Synthetic cannabinoids bind far more powerfully to CB1 receptors than THC does, and many of them have unpredictable metabolites that the liver may struggle to process safely. The risk profile of synthetic cannabinoids should not be conflated with that of plant-derived marijuana, but people who use synthetic products under the assumption that they’re getting a “similar” experience to cannabis are taking on a meaningfully higher liver risk.
Contaminants You Didn’t Sign Up For
Cannabis itself is not the only potential source of liver stress when someone uses marijuana. Depending on how and where it was grown, cannabis can carry contaminants including heavy metals, pesticides, and microbial pathogens. Heavy metals like lead and cadmium are known hepatotoxins, and pesticide residues metabolized in the liver add to the organ’s workload. The direct human toxicity of these contaminants in cannabis is poorly quantified, in part because research on cannabis quality control has been historically neglected.22PubMed Central. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects
Products from regulated dispensaries are generally tested for major contaminants, though testing standards vary by state and loopholes exist. Black-market cannabis and unregulated CBD products carry higher contamination risk. If you’re concerned about liver health and choose to use cannabis, sourcing matters more than most people realize. A liver enzyme elevation attributed to “marijuana” in a clinical setting could, in some cases, reflect the pesticide riding along with it rather than the cannabinoid itself.
When Liver Monitoring Makes Sense
Given all of this, who should actually worry about getting their liver enzymes checked? The clearest case is anyone taking prescription CBD, especially alongside valproate or other anti-seizure medications. The FDA-approved CBD product Epidiolex includes liver-monitoring guidance on its label for exactly this reason. Patients typically get baseline liver tests before starting, then periodic checks during the first several months of treatment.
For recreational or low-dose consumer CBD users, the picture is murkier. The risk is almost certainly lower at 25 to 50 mg per day than at 1,500 mg per day, but “almost certainly” is not the same as “proven safe.” If you take CBD regularly and also take other medications metabolized by the liver, mentioning it to your doctor and getting periodic liver panels is reasonable.
For people who primarily use THC-dominant marijuana, routine liver monitoring probably isn’t necessary if your liver is otherwise healthy and you’re not a heavy daily user. But if you have pre-existing liver disease, particularly cirrhosis or active hepatitis, the research raises enough flags that honest conversations with your hepatologist are warranted. The endocannabinoid system is deeply embedded in liver physiology, and adding external cannabinoids to an already compromised liver introduces variables that nobody can fully predict yet.